Quote:

---

Chiral Pharma Corporation, a subsidiary of Philippine New Marketlink Pharmaceutical Corporation (NMPC), to register leronlimab (PRO 140) for potential approval from the local Food and Drug Administration to treat patients with COVID-19 in the Philippines.

---

Doesn't exactly say "we applied for approval" but damn close. Again, different system over there, so you and I can parse and interpret the PR language all weekend, but Cytodyn could very well already be in the approval-pipeline.